ag-24322
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00147485)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cyclin-dependent kinase 2INHIBITOR
CDK2 inhibitor
- Cyclin-dependent kinase 4INHIBITOR
CDK4 inhibitor
- Cyclin-dependent kinase 1INHIBITOR
CDK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCNCc1cncc(-c2ccc3c(c2)/C(=C2/N=c4cc(F)cc(F)c4=N2)NN3)c1C- Mol. weight
- 418.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545420 ↗
Also known as
- ag024322
- ag 024322
- ag-024322
- ag-024322
- ag-024322
- ag-024322
- ag-24322
- ag-24322
- ag-24322
- n-((5-(3-(4,6-difluoro-1h-benzimidazol-2-yl)-1h-indazol-5-yl)-4-methylpyridin-3-yl)methyl)ethanamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00147485 | Phase 1 | Dec 1, 2004 | Pfizer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 1 | 1 | 1 | 2004 |
1 organizations
Page 1 / 1